Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• CD8+ T cells play a critical role in adaptive immunity, mediating anti-viral and anti-tumor responses.
• Dasatinib is a tyrosine kinase inhibitor used in cancer therapy, with potential immunomodulatory effects.
• Understanding dasatinib's impact on T cell function is crucial for managing its side effects and exploring new therapeutic applications.

Purpose of the Study:

• To investigate the inhibitory effects of dasatinib on CD8+ T cell proliferation, function, and signaling.
• To elucidate the molecular mechanisms underlying dasatinib's impact on T cell receptor (TCR) and NF-kappaB signaling pathways.
• To compare the potency of dasatinib with imatinib on specific signaling events in T cells.

Main Methods:

• CD8+ T cell proliferation and cell cycle were assessed using carboxyfluorescein diacetate succinimidyl ester and 5-bromo-2-deoxyuridine.
• T cell function was evaluated through tetramer staining and ELISPOT assays for viral and leukemia-antigen-specific responses.
• Western blotting was employed to analyze signaling pathways, including TCR, NF-kappaB, and Src.

Main Results:

• Dasatinib demonstrated dose-dependent inhibition of CD8+ T cell proliferation, arresting cells in the G0/G1 phase.
• A reduction in interferon-gamma and granzyme B secretion was observed, indicating impaired T cell function.
• Dasatinib downregulated phosphorylation of key molecules in TCR and NF-kappaB signaling cascades, with greater potency than imatinib on Src and TCR signaling.

Conclusions:

• Dasatinib impairs CD8+ T cell proliferation and function by modulating TCR and NF-kappaB signaling without inducing apoptosis.
• These effects may influence graft-versus-leukemia and graft-versus-host disease in allogeneic stem cell transplantation.
• Dasatinib exhibits potential as a novel immunosuppressant agent.